C4 Therapeutics
About C4 Therapeutics
C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder and CEO: Marc Cohen
Founders: Ken Anderson, Marc Cohen, Jay Bradner and Nathanael Gray
CSO: Andy Phillips
CAO: Andrea Armstrong
CBO: Tom Needham
JOBS:
Please click here for C4 job opportunities.
FOLLOW C4 THERAPEUTICS:
Tweets by C4 Therapeutics
72 articles with C4 Therapeutics
-
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
5/16/2022
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.
-
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/5/2022
C4 Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022, as well as recent business highlights.
-
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
-
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
3/16/2022
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, announced the appointment of Utpal Koppikar, MBA, to its board of directors.
-
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
3/9/2022
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 for the treatment of soft tissue sarcoma.
-
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/8/2022
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
-
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
2/24/2022
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported business highlights and financial results for the year ended December 31, 2021.
-
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
1/10/2022
C4 Therapeutics, Inc. announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio.
-
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
C4 Therapeutics, Inc. today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.
-
C4 Therapeutics Added to NASDAQ Biotechnology Index
12/17/2021
C4 Therapeutics, Inc. today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
11/10/2021
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today reported business highlights and financial results for the third quarter of 2021.
-
This followed a report that found that some trustees had, perhaps, taken advantage of this close connection with startups and research programs for their financial gain.
-
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
8/11/2021
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, reported business highlights and financial results for the second quarter of 2021.
-
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
8/11/2021
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455 for the treatment of multiple myeloma.
-
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma
6/21/2021
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins.
-
C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
6/21/2021
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an underwritten public offering of 4,887,500 shares of its common stock.
-
C4 Therapeutics Announces Pricing of Public Offering
6/16/2021
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share.
-
C4 Therapeutics Launches Proposed Public Offering
6/14/2021
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
-
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies
6/14/2021
C4 Therapeutics, Inc. announced that the first patient has been dosed in the Company’s clinical trial of CFT7455, an orally bioavailable MonoDAC™ targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.